Immune Response Corporation

HIV-focused biopharmaceutical company completes drug studies in Italy and Spain

Published in Aging and Elder Health Week, February 13th, 2005

The Immune Response Corporation (IMNR), a biopharmaceutical immune-based therapy company in HIV and multiple sclerosis (MS), announced that the company has completed 2 phase 2 clinical trials, one in Italy and one in Spain, investigating its HIV immune-based therapeutic Remune in HIV-positive subjects.

The trial in Spain, called Remit, included 39 patients who had previously received Remune in an open label study, who were then randomized to receive blinded Remune or Incomplete Freud's Adjuvant (IFA) during Remit, and a comparative control group of 19 subjects.

This trial was designed as an exploratory phase 2 trial with multiple endpoints to give...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Aging and Elder Health Week

Source: Aging and Elder Health Week (2005-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry